Targeted agents for second-line treatment of advanced hepatocellular carcinoma

Over the past ten years, sorafenib, a multikinase inhibitor, has been the standard of care for patients with unresectable hepatocellular carcinoma (HCC) and well-preserved liver function. Recently, lenvatinib, a different multikinase inhibitor, was shown to be non-inferior to sorafenib, in terms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Personeni, Nicola, Pressiani, Tiziana, Bozzarelli, Silvia, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815920/
https://www.ncbi.nlm.nih.gov/pubmed/31662820
http://dx.doi.org/10.4251/wjgo.v11.i10.788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815920/
https://www.ncbi.nlm.nih.gov/pubmed/31662820
http://dx.doi.org/10.4251/wjgo.v11.i10.788

Ejemplares similares